- Full text PDF available (1)
- This year (0)
- Last 5 years (3)
- Last 10 years (3)
may make verbatim copies of this document for non-commercial purposes by any means, provided that this copyright notice appears on all such copies.
119 Background: Oncotype Dx is a twenty-one gene prognostic assay traditionally used to predict response to systemic chemotherapy in early stage, hormone positive, node negative, HER2neu negative breast cancer. We evaluated the prevalence of Oncotype Dx testing in a local community oncology setting, co-relation with patient age and co-relation of recurrence… (More)
62 Background: ECOG Performance Status (PS) plays a pivotal role in the decision to treat patients with NSCLC Stage IV. The current ASCO guidelines for offering cytotoxic chemotherapy in stage IV NSCLC state that a PS of ≤2 can be considered for intravenous treatment. The goal of our retrospective evaluation was to evaluate treatment patterns based on ECOG… (More)